Published in Food and Drug Law Weekly, June 25th, 2004
The letter relates only to certain promotional literature and is not related to Advate's performance, clinical data, or processing. The concerns outlined by the FDA pertain specifically to the display of appropriate language relating to labeled side effects and supporting data for the statements included in the printed materials.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.